Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Acquisition of Marketing Approval for VYVANSE Capsule 20mg/30mg for Treatment of Attention Deficit Hyperactivity Disorder

firstwordpharmaApril 14, 2019

Tag: VYVANSE Capsule , Deficit Hyperactivity , disorder

PharmaSources Customer Service